The precise diagnosis and treatment of hepatocellular carcinoma （HCC） face major challenges such as the complexity of tumor microenvironment， treatment resistance， and a high risk of recurrence and metastasis. In recent years， ultrasound technology has moved beyond its traditional role in screening and localization， gradually evolving into a multidimensional therapeutic platform capable of energy activation， targeted delivery， local ablation， immune modulation， and therapeutic feedback. This article systematically reviews the latest advances in the basic research on ultrasound techniques in HCC treatment and integrated management. In terms of treatment， intervention strategies represented by microbubble/nanobubble-mediated delivery， sonodynamic therapy， high-intensity focused ultrasound， and histotripsy not only enable in situ physical destruction of lesions， but also effectively reverse tumor immune tolerance networks through deep synergy with sonogenetics， metabolic reprogramming， and immunochemotherapy. In terms of integrated management， novel sonosensitive nanodelivery systems provide a platform for energy activation and targeted controlled release. To address the translational bottlenecks in this field， it is recommended to develop standardized consensus on preclinical therapeutic ultrasound parameters， in order to establish a new translational paradigm for individualized precise diagnosis and treatment of HCC.

Lower-extremity vascular disease has a high morbidity rate and often leads to disability and death in its advanced stages. Although angiography-guided endovascular intervention is the primary treatment for peripheral vascular disease, it frequently fails to detect subtle lumen features and falls short of meeting the increasing clinical need for precise management. Intravascular ultrasound (IVUS) merges noninvasive ultrasound imaging with invasive catheterization techniques, providing 360° imaging of the vascular cross-section and delivering accurate information about lesion morphology. IVUS has been crucial in supporting decisionmaking for preoperative assessment, intraoperative monitoring, and postoperative optimization during vascular interventions. This review aims to summarize the latest applications of IVUS in lower-extremity vascular disease, discuss its strengths and limitations, and explore future directions for its use.

Lower-extremity vascular disease has a high morbidity rate and often leads to disability and death in its advanced stages. Although angiography-guided endovascular intervention is the primary treatment for peripheral vascular disease, it frequently fails to detect subtle lumen features and falls short of meeting the increasing clinical need for precise management. Intravascular ultrasound (IVUS) merges noninvasive ultrasound imaging with invasive catheterization techniques, providing 360° imaging of the vascular cross-section and delivering accurate information about lesion morphology. IVUS has been crucial in supporting decisionmaking for preoperative assessment, intraoperative monitoring, and postoperative optimization during vascular interventions. This review aims to summarize the latest applications of IVUS in lower-extremity vascular disease, discuss its strengths and limitations, and explore future directions for its use.

Lower-extremity vascular disease has a high morbidity rate and often leads to disability and death in its advanced stages. Although angiography-guided endovascular intervention is the primary treatment for peripheral vascular disease, it frequently fails to detect subtle lumen features and falls short of meeting the increasing clinical need for precise management. Intravascular ultrasound (IVUS) merges noninvasive ultrasound imaging with invasive catheterization techniques, providing 360° imaging of the vascular cross-section and delivering accurate information about lesion morphology. IVUS has been crucial in supporting decisionmaking for preoperative assessment, intraoperative monitoring, and postoperative optimization during vascular interventions. This review aims to summarize the latest applications of IVUS in lower-extremity vascular disease, discuss its strengths and limitations, and explore future directions for its use.

Lower-extremity vascular disease has a high morbidity rate and often leads to disability and death in its advanced stages. Although angiography-guided endovascular intervention is the primary treatment for peripheral vascular disease, it frequently fails to detect subtle lumen features and falls short of meeting the increasing clinical need for precise management. Intravascular ultrasound (IVUS) merges noninvasive ultrasound imaging with invasive catheterization techniques, providing 360° imaging of the vascular cross-section and delivering accurate information about lesion morphology. IVUS has been crucial in supporting decisionmaking for preoperative assessment, intraoperative monitoring, and postoperative optimization during vascular interventions. This review aims to summarize the latest applications of IVUS in lower-extremity vascular disease, discuss its strengths and limitations, and explore future directions for its use.

Lower-extremity vascular disease has a high morbidity rate and often leads to disability and death in its advanced stages. Although angiography-guided endovascular intervention is the primary treatment for peripheral vascular disease, it frequently fails to detect subtle lumen features and falls short of meeting the increasing clinical need for precise management. Intravascular ultrasound (IVUS) merges noninvasive ultrasound imaging with invasive catheterization techniques, providing 360° imaging of the vascular cross-section and delivering accurate information about lesion morphology. IVUS has been crucial in supporting decisionmaking for preoperative assessment, intraoperative monitoring, and postoperative optimization during vascular interventions. This review aims to summarize the latest applications of IVUS in lower-extremity vascular disease, discuss its strengths and limitations, and explore future directions for its use.

Contrast-enhanced ultrasound（CEUS），as a non-invasive imaging technique，has been widely applied in the characterization of focal liver lesions（FLLs）. By intravenously injecting contrast agents and using specific low mechanical index imaging techniques，CEUS not only provides high spatial and temporal resolution，but also enables dynamic assessment of blood flow perfusion in both large vessels and microvessels，including capillaries in the liver. However，CEUS is highly operator-dependent. The quantitative analysis of time-intensity curves in dynamic contrast-enhanced ultrasound（DCE-US）can provide further information，overcome the subjectivity limitations of traditional CEUS and improve the accuracy of diagnosis and treatment in FLLs. This review discusses the theoretical basis of DCE-US and its quantitative analysis methods，their applications in the diagnosis and treatment of FLLs，limitations，and future directions.

Contrast-enhanced ultrasound（CEUS），as a non-invasive imaging technique，has been widely applied in the characterization of focal liver lesions（FLLs）. By intravenously injecting contrast agents and using specific low mechanical index imaging techniques，CEUS not only provides high spatial and temporal resolution，but also enables dynamic assessment of blood flow perfusion in both large vessels and microvessels，including capillaries in the liver. However，CEUS is highly operator-dependent. The quantitative analysis of time-intensity curves in dynamic contrast-enhanced ultrasound（DCE-US）can provide further information，overcome the subjectivity limitations of traditional CEUS and improve the accuracy of diagnosis and treatment in FLLs. This review discusses the theoretical basis of DCE-US and its quantitative analysis methods，their applications in the diagnosis and treatment of FLLs，limitations，and future directions.

Objective:To clarify the changes of intrahepatic ultrasound hemodynamics before and after hepatic artery thrombosis (HAT) after liver transplantation (LT), providing early warning and anticoagulation guidance to clinicians.Methods:The clinical data of patients who underwent liver transplantation at Zhongshan Hospital of Fudan University between June 2006 and October 2022 were retrospectively analyzed, 47 patients with a diagnosis of HAT confirmed by DSA (digital subtraction angiography) were included in the HAT group, and 71 patients without vascular complications were included in the non-HAT group. Differences in peak flow velocity (PSV), resistance index (RI), and portal vein velocity (PVV) were compared between the two groups. Logistic regression analysis was used to determine the relationship between postoperative PSV decline and HAT occurrence, while ROC curve were used to determine the critical value and evaluate the diagnostic efficacy. Patients with HAT were divided into well-treatment group and poor-treatment group according to whether the blood flow was restored after multiple surgeries or thrombolytic treatments. The changes of early intrahepatic hemodynamics after surgical or thrombolytic therapy were compared between the two groups.Results:①A decrease in PSV of the transplanted hepatic artery was measured 1 d before HAT, and PSV<0.39 m/s predicted thrombus formation with a sensitivity of 0.70, specificity of 0.86, and the AUC was 0.83. ②After treatment, PSV in the HAT group increased immediately, approaching the normal level on the 2nd day. In the well-treatment group, PSV and PVV reached normal levels on the first day after treatment, which were significantly higher than the corresponding values in the poor-treatment group ( P=0.030, 0.021). Conclusions:In the early stage after liver transplantation, a PSV<0.39 m/s is related to the occurrence of HAT thrombosis 1 d later. A significant increase in PSV on the first day after treatment indicates a good treatment response, and there is no need for further DSA re-examination or increasing the number of thrombolysis.

Objective: To prospectively evaluate the outcomes of ultrasound (US)-guided radiofrequency ablation (RFA) in tertiary hyperparathyroidism (THPT). Materials and Methods: Patients with THPT underwent RFA between September 2017 and January 2022. Laboratory parameters, including serum intact parathyroid hormone (iPTH) levels, were monitored for 48 months after RFA and compared with the levels at baseline. Complications related to RFA and changes in hyperparathyroidism-related clinical symptoms were recorded before and after RFA. Results: A total of 42 patients with THPT were recruited for this study. Ultimately, 36 patients with renal failure and 2 patients who underwent successful renal transplantation (male:female, 17:21; median age, 54.5 years) were enrolled. The follow-up time was 21.5 ± 19.0 months in the 36 patients with renal failure. In these 36 patients, iPTH levels were significantly decreased to 261.1 pg/mL at 48 months compared with the baseline value of 1284.9 pg/mL (P = 0.012). Persistent hyperparathyroidism, defined as iPTH levels maintained at > 585.0 pg/mL for 6 months after treatment, occurred in 4.0% of patients (1/25). Recurrent hyperparathyroidism, defined as iPTH levels > 585.0 pg/mL after 6 months, were 4.0% (1/25) and 0.0% (0/9) at 6 months and 4 years after treatment, respectively. In two patients with THPT after successful renal transplantation, iPTH decreased from the baseline value of 242.5 and 115.9 pg/mL to 171.0 and 62.0 pg/mL at 6 months after treatment. All complications resolved within 6 months of ablation without medical intervention, except in 10.5% (4/38) patients with permanent hypocalcemia. The overall symptom recovery rate was 58.8% (10/17). The severity scores for bone pain, arthralgia, and itchy skin associated with hyperparathyroidism improved after treatment (P < 0.05). Conclusion US-guided RFA is an effective and safe alternative to surgery in the treatment of patients with TPTH and improves hyperparathyroidism-related clinical symptoms.Keywords: Ultrasound; Radiofrequency ablation; Te